Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma

Yi Wang, Mamoru Harada, Hirohisa Yano, Sachiko Ogasawara, Hiroko Takedatsu, Yoshimi Arima, Satoko Matsueda, Akira Yamada, Kyogo Itoh

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Prostatic acid phosphatase (PAP) is one of the prostate-related antigens that are applicable to specific immunotherapy for patients with prostate cancer. In this study, we determined whether or not PAP could be a target molecule in specific immunotherapy for patients with nonprostate cancer. A variety of adenocarcinoma cell lines were examined for their PAP expression at the mRNA and protein levels by reverse transcription polymerase chain reaction and western blot analysis, respectively. Considerable percentages of colon, gastric, and breast cancer cell lines were found to be positive for PAP at both the mRNA and the protein levels. The PAP expression in cancer tissues was also confirmed by immunohistochemical staining. In addition, we examined whether cancer-reactive cytotoxic T lymphocytes (CTLs) could be induced from peripheral blood mononuclear cells (PBMCs) of human leukocyte antigen (HLA) A24+ nonprostate cancer patients by in vitro stimulation with a PAP peptide. As a result, tumor-specific CTLs could be induced from the PBMCs of HLA-A24 + colon and gastric cancer patients. Their cytotoxicity against HLA-A24+ cancer cells was dependent on PAP peptide-specific and CD8+ T cells. These findings indicate that PAP could be a target molecule in specific immunotherapy for patients with nonprostate adenocarcinomas including colon and gastric cancers.

Original languageEnglish
Pages (from-to)535-541
Number of pages7
JournalJournal of Immunotherapy
Volume28
Issue number6
DOIs
Publication statusPublished - 2005 Jan 1
Externally publishedYes

Fingerprint

Immunotherapy
Adenocarcinoma
HLA Antigens
Colonic Neoplasms
Stomach Neoplasms
Neoplasms
Cytotoxic T-Lymphocytes
Blood Cells
Cell Line
Messenger RNA
Peptides
prostatic acid phosphatase
Reverse Transcription
Prostate
Prostatic Neoplasms
Proteins
Western Blotting
Staining and Labeling
Breast Neoplasms
T-Lymphocytes

Keywords

  • Adenocarcinoma
  • Cytotoxic T lymphocytes
  • Immunotherapy
  • Peptide
  • Prostatic acid phosphatase

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. / Wang, Yi; Harada, Mamoru; Yano, Hirohisa; Ogasawara, Sachiko; Takedatsu, Hiroko; Arima, Yoshimi; Matsueda, Satoko; Yamada, Akira; Itoh, Kyogo.

In: Journal of Immunotherapy, Vol. 28, No. 6, 01.01.2005, p. 535-541.

Research output: Contribution to journalArticle

Wang, Yi ; Harada, Mamoru ; Yano, Hirohisa ; Ogasawara, Sachiko ; Takedatsu, Hiroko ; Arima, Yoshimi ; Matsueda, Satoko ; Yamada, Akira ; Itoh, Kyogo. / Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. In: Journal of Immunotherapy. 2005 ; Vol. 28, No. 6. pp. 535-541.
@article{e5e17b74a2d349e4b2b7967a66686a2c,
title = "Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma",
abstract = "Prostatic acid phosphatase (PAP) is one of the prostate-related antigens that are applicable to specific immunotherapy for patients with prostate cancer. In this study, we determined whether or not PAP could be a target molecule in specific immunotherapy for patients with nonprostate cancer. A variety of adenocarcinoma cell lines were examined for their PAP expression at the mRNA and protein levels by reverse transcription polymerase chain reaction and western blot analysis, respectively. Considerable percentages of colon, gastric, and breast cancer cell lines were found to be positive for PAP at both the mRNA and the protein levels. The PAP expression in cancer tissues was also confirmed by immunohistochemical staining. In addition, we examined whether cancer-reactive cytotoxic T lymphocytes (CTLs) could be induced from peripheral blood mononuclear cells (PBMCs) of human leukocyte antigen (HLA) A24+ nonprostate cancer patients by in vitro stimulation with a PAP peptide. As a result, tumor-specific CTLs could be induced from the PBMCs of HLA-A24 + colon and gastric cancer patients. Their cytotoxicity against HLA-A24+ cancer cells was dependent on PAP peptide-specific and CD8+ T cells. These findings indicate that PAP could be a target molecule in specific immunotherapy for patients with nonprostate adenocarcinomas including colon and gastric cancers.",
keywords = "Adenocarcinoma, Cytotoxic T lymphocytes, Immunotherapy, Peptide, Prostatic acid phosphatase",
author = "Yi Wang and Mamoru Harada and Hirohisa Yano and Sachiko Ogasawara and Hiroko Takedatsu and Yoshimi Arima and Satoko Matsueda and Akira Yamada and Kyogo Itoh",
year = "2005",
month = "1",
day = "1",
doi = "10.1097/01.cji.0000175490.26937.22",
language = "English",
volume = "28",
pages = "535--541",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma

AU - Wang, Yi

AU - Harada, Mamoru

AU - Yano, Hirohisa

AU - Ogasawara, Sachiko

AU - Takedatsu, Hiroko

AU - Arima, Yoshimi

AU - Matsueda, Satoko

AU - Yamada, Akira

AU - Itoh, Kyogo

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Prostatic acid phosphatase (PAP) is one of the prostate-related antigens that are applicable to specific immunotherapy for patients with prostate cancer. In this study, we determined whether or not PAP could be a target molecule in specific immunotherapy for patients with nonprostate cancer. A variety of adenocarcinoma cell lines were examined for their PAP expression at the mRNA and protein levels by reverse transcription polymerase chain reaction and western blot analysis, respectively. Considerable percentages of colon, gastric, and breast cancer cell lines were found to be positive for PAP at both the mRNA and the protein levels. The PAP expression in cancer tissues was also confirmed by immunohistochemical staining. In addition, we examined whether cancer-reactive cytotoxic T lymphocytes (CTLs) could be induced from peripheral blood mononuclear cells (PBMCs) of human leukocyte antigen (HLA) A24+ nonprostate cancer patients by in vitro stimulation with a PAP peptide. As a result, tumor-specific CTLs could be induced from the PBMCs of HLA-A24 + colon and gastric cancer patients. Their cytotoxicity against HLA-A24+ cancer cells was dependent on PAP peptide-specific and CD8+ T cells. These findings indicate that PAP could be a target molecule in specific immunotherapy for patients with nonprostate adenocarcinomas including colon and gastric cancers.

AB - Prostatic acid phosphatase (PAP) is one of the prostate-related antigens that are applicable to specific immunotherapy for patients with prostate cancer. In this study, we determined whether or not PAP could be a target molecule in specific immunotherapy for patients with nonprostate cancer. A variety of adenocarcinoma cell lines were examined for their PAP expression at the mRNA and protein levels by reverse transcription polymerase chain reaction and western blot analysis, respectively. Considerable percentages of colon, gastric, and breast cancer cell lines were found to be positive for PAP at both the mRNA and the protein levels. The PAP expression in cancer tissues was also confirmed by immunohistochemical staining. In addition, we examined whether cancer-reactive cytotoxic T lymphocytes (CTLs) could be induced from peripheral blood mononuclear cells (PBMCs) of human leukocyte antigen (HLA) A24+ nonprostate cancer patients by in vitro stimulation with a PAP peptide. As a result, tumor-specific CTLs could be induced from the PBMCs of HLA-A24 + colon and gastric cancer patients. Their cytotoxicity against HLA-A24+ cancer cells was dependent on PAP peptide-specific and CD8+ T cells. These findings indicate that PAP could be a target molecule in specific immunotherapy for patients with nonprostate adenocarcinomas including colon and gastric cancers.

KW - Adenocarcinoma

KW - Cytotoxic T lymphocytes

KW - Immunotherapy

KW - Peptide

KW - Prostatic acid phosphatase

UR - http://www.scopus.com/inward/record.url?scp=26444432150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444432150&partnerID=8YFLogxK

U2 - 10.1097/01.cji.0000175490.26937.22

DO - 10.1097/01.cji.0000175490.26937.22

M3 - Article

VL - 28

SP - 535

EP - 541

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 6

ER -